Comparison · NCT02070757-sae
Ceftolozane/Tazobactam vs Meropenem: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ceftolozane/Tazobactam vs Meropenem: serious adverse events. Trial comparisons, record NCT02070757-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02070757-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.421 | 0.371 | 0.473 | wilson | |
| Risk in group 2 | 0.359 | 0.311 | 0.41 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0617 | -0.0095 | 0.132 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.17 | 0.975 | 1.41 | log | |
| Odds ratio, group 1 over group 2 | 1.3 | 0.96 | 1.75 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Ceftolozane/Tazobactam than on Meropenem | 16.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ceftolozane/Tazobactam | Participants receive 3000 mg ceftolozane/tazobactam (comprising 2000 mg ceftolozane and 1000 mg tazobactam) administered as an IV infusion every 8 hours (q8h). | 152 | 361 | EG000 |
| Group 2 | Meropenem | Participants receive 1000 mg meropenem administered as an IV infusion q8h. | 129 | 359 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From first dose of study drug up to 35 days after last dose of study drug (Up to ~Day 50)
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)
- NCT number
- NCT02070757
- Phases
- PHASE3
- Conditions
- Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia, Lung Diseases
- Interventions
- Ceftolozane/tazobactam, Meropenem
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Results first posted
- 2019-05-31
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02070757?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02070757-sae